Breaking News
November 24, 2017 - Video game improves balance in youth with autism
November 24, 2017 - Chromatrap introduces easy-to-use range of DNA kits for molecular biology applications
November 24, 2017 - Bacteria in the intestine can play important pacemaker role in peristalsis
November 24, 2017 - Resistance training promotes environmental quality of life and sense of coherence in older people
November 24, 2017 - Research suggests genome’s spatial organization as important switch for defining cell types
November 24, 2017 - Study highlights need for more clinical trials to improve treatment of children with heart disease
November 24, 2017 - Quickly Treating Mini-Stroke Can Cut Risk for Future Stroke
November 24, 2017 - Inclusion in mainstream school can exacerbate feelings of being ‘different’ in pupils with autism spectrum conditions
November 24, 2017 - Fat-busting ingredients in cinnamon
November 24, 2017 - IMeasureU introduces IMU Step for tracking movements of professional, amateur athletes
November 24, 2017 - Study uncovers key mechanism by which tumors develop resistance to radiation therapy
November 24, 2017 - This Thanksgiving, carve out time for lively discourse on end-of-life wishes
November 24, 2017 - Creutzfeldt-Jakob disease patients harbor infectious prions in their skin
November 24, 2017 - Call for ‘renewed focus’ on deadly threat from antibiotic resistance
November 24, 2017 - 14 signs your daughter may have ADHD
November 24, 2017 - ACA appears to have encouraged more people to use preventive care for heart health
November 23, 2017 - UVA researchers developing new tool to help cancer patients make complex care decisions
November 23, 2017 - SITC releases first consensus recommendations on managing immunotherapy side effects
November 23, 2017 - Research shows major shift in eye surgeries from hospitals to ambulatory surgery centers
November 23, 2017 - Multiple sclerosis drug can beat obstinate bacteria
November 23, 2017 - Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis
November 23, 2017 - Heart disease risk factors linked to walking difficulties in people under age of 78
November 23, 2017 - UVA scientists working to find end-around method to stop triple-negative breast cancer
November 23, 2017 - Researchers develop new tool to share clinico-genomic data
November 23, 2017 - New analysis identifies five distinct patient clusters that may need different approaches to manage asthma
November 23, 2017 - Study shows education and poverty affect outcomes of total knee replacement
November 23, 2017 - Research paves way for development of vaccines against mycoplasma bacteria
November 23, 2017 - Season of festivities can increase opportunities to overindulge in alcohol
November 23, 2017 - Methotrexate drug holiday improves flu vaccine efficacy in rheumatoid arthritis patients
November 23, 2017 - Study identifies signaling pathway essential for growth of new blood vessels
November 23, 2017 - OBD presents results of immunotherapy studies at FNIH Biomarker Consortium Cancer Steering Committee’s annual meeting
November 23, 2017 - New study shows how SNO reaction may contribute to Parkinson’s disease
November 23, 2017 - Study highlights need to improve quality of cardiovascular care for HIV-positive adults
November 23, 2017 - New intelligence tool provides clarity to scientists in booming immuno-oncology field
November 23, 2017 - Cancer Survivors Can Develop PTSD, Too
November 23, 2017 - One step closer toward a treatment for Alzheimer’s disease?
November 23, 2017 - Scientists detect pathological prion protein in skin of CJD patients
November 23, 2017 - Bacterial colonization can function as a pacemaker for the intestine, study reveals
November 23, 2017 - Preclinical study shows clear path toward effective treatment for rare bone disease
November 23, 2017 - Displaced Puerto Ricans face obstacles getting health care
November 23, 2017 - High-intensity exercise improves memory, study finds
November 23, 2017 - Researchers compare shunts and stents to maintain blood flow in infants with heart disease
November 23, 2017 - Gold nanoparticles could potentially help in more effective drug delivery
November 23, 2017 - Moderate coffee consumption more likely to provide beneficial health outcomes
November 23, 2017 - ESMO Consortium Study advocates for equal access to quality cancer treatment across Asia
November 23, 2017 - Gut bacteria at young age can contribute to MS onset and progression, study suggests
November 23, 2017 - Australian government urged to sue tobacco companies
November 23, 2017 - OB/GYN vs PCP: Who Should Handle Sexual Health?
November 23, 2017 - A Teen Mom’s Stress May Harm Her Heart: MedlinePlus Health News
November 23, 2017 - How SORLA protects against Alzheimer’s disease
November 23, 2017 - Newly discovered drug-like compound may revolutionize treatment of autoimmune diseases
November 23, 2017 - Comprehensive review finds increasing number of new heart failure cases in the UK
November 23, 2017 - Leishmania adaptation to environmental changes results from frequent chromosomal amplifications
November 23, 2017 - People who use indoor firing ranges at risk of lead poisoning
November 23, 2017 - Tiny robots could pave way for treating illness in hard-to-reach areas of the body
November 23, 2017 - Study finds smokers wrongly believe Natural American Spirit cigarettes are healthier
November 23, 2017 - Cancer patients willing to swap drug efficacy for reduced risk of adverse events
November 23, 2017 - Oncologists find new biomarker for breast cancer having poor prognosis
November 23, 2017 - Scientists show how diaper phantoms can improve tumor measurements
November 23, 2017 - Metabolites significantly affected in chronic kidney disease, study finds
November 23, 2017 - AR and VR technologies hold potential to increase attractiveness of healthy foods
November 23, 2017 - Amazon Filters offers SupaPore H0P filters for fermentation applications
November 23, 2017 - FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma
November 23, 2017 - Does Sex Really Trigger Cardiac Arrest?: MedlinePlus Health News
November 23, 2017 - Baby-boomers and millennials more afflicted by the opioid epidemic
November 23, 2017 - UNC Lineberger professor receives The Leukemia & Lymphoma Society grant for immunotherapy research
November 23, 2017 - Researchers question exclusion of people with prior cancer history from clinical trials
November 23, 2017 - New mechanism in cancer cells to disarm attacking immune cells, study reveals
November 23, 2017 - Most U.S. Parents Can’t Find Good Childcare: Survey
November 23, 2017 - Alpha-fetoprotein (AFP) Test: MedlinePlus Lab Test Information
November 23, 2017 - Opening windows and doors may improve sleep
November 23, 2017 - Research shows how HLF gene affects blood cell development
November 23, 2017 - Deaths due to diabetes higher than expected in Germany
November 23, 2017 - Study finds improvement in men’s health and negative health trend among women
November 23, 2017 - Study finds specific tumor environment that stimulates cancer cells to metastasize
November 23, 2017 - Problems with your hospital care? Speak up!
November 23, 2017 - Thyroid cancer survivors have higher risk for aging-related diseases
November 23, 2017 - Is a common shoulder surgery useless?
November 23, 2017 - Palliative care services help cancer patients
November 23, 2017 - Anti-diabetic drug can enhance repair of UV-induced DNA damage in cells of ‘Moon children’
Lower is Better for PBC Candidate Drug

Lower is Better for PBC Candidate Drug

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

WASHINGTON — An investigational drug for primary biliary cholangitis (PBC) that had safety issues at high doses did better at lower doses, with good efficacy and fewer adverse events, a researcher said here.

A proof-of-concept study of the oral drug seladelpar was stopped after high doses were efficacious but also were linked to transient elevations of liver enzymes, according to Gideon Hirschfield, PhD, of the University of Birmingham in England.

Interim analysis of a phase II randomized trial with lower doses, however, showed similar efficacy without the safety issues, Hirschfield told a late-breaker session at the Liver Meeting, the annual conference of the American Association for the Study of Liver Diseases.

Indeed, at the lower doses — 5 and 10 mg/day — the drug decreased liver enzymes rather than elevating them, Hirschfield said.

The drug activates the peroxisome proliferator-activated receptor (PPAR) delta, which governs several biological processes and is thought to play a role in various chronic diseases, including diabetes, obesity, atherosclerosis, and some cancers.

It’s hoped to be useful in PBC, Hirschfield said, because it appears to prompt improvements in bile acid secretion, homeostasis, liver fibrosis, inflammation, and metabolism.

The study findings are “encouraging,” given that there are few treatment options for PBC, commented Raymond Chung, MD, of Massachusetts General Hospital in Boston, who was not part of the study but who co-moderated the session at which it was presented.

He added that people with PBC — especially those who are refractory to current treatments — are rare.

“What we hope to see — given the pleotropic effects of this compound on bile acid synthesis, on cholesterol metabolism — the hope is that this could be applied to other broader liver diseases, like non-alcoholic fatty liver,” he told MedPage Today.

In the wake of the earlier trial, Hirschfield said, investigators enrolled 24 patients and randomly assigned them in an open-label fashion to either 5 or 10 mg of the drug. The goal was to see what effect the drug had on alkaline phosphatase, as well as on liver enzymes and total bilirubin.

Click here for video comments from study authors and discussants at AASLD 2017.

The study population was at high risk for liver damage owing to PBC — most were intolerant of the first-line drug for the condition, and all had highly elevated alkaline phosphatase and liver enzymes.

The study called for them to take the drug daily for 12 weeks and then to be rolled into an 18-week extension study with the option for dose adjustment if needed. Hirschfield presented interim outcomes after the first 12 weeks of therapy.

For both doses, he reported, alkaline phosphatase levels dropped sharply over the first 4 weeks, finishing 39% lower than baseline for the low dose and 45% lower for the high dose. There was no statistical difference between the groups.

At 12 weeks, 18% of those taking the low dose and 45% of those on the high dose had alkaline phosphatase below the upper limit of normal, he reported. The drug was also associated with reduced cholestasis, decreases in transaminases, lower LDL-cholesterol, and reduced inflammation, Hirschfield said.

On the tolerability front, the drug was not seen to increase risk of pruritus, one of the most troublesome symptoms of PBC, he said. There were no serious adverse events, he added.

In the light of the findings, Hirschfield said, the study design has been modified: The researchers will add participants to bring the total to 49 in each arm, and lengthen the extension study to 52 weeks.

As well, to see if efficacy can be obtained with even lower doses, the investigators will add a 2-mg arm with 18 patients.

A phase III trial is intended to start next year, he said.

The study had support from Cymabay Therapeutics, maker of seladelpar. Hirschfield disclosed relationships with Intercept Pharma, Cymabay, Takeda, BioTie, Falk Pharma, and GSK.

Chung disclosed relationships with Alnylam, AbbVie, BMS, Boehringer Ingelheim, Gilead, Janssen, and Merck.


Tagged with:

About author

Related Articles